CagriSema: Novo Nordisk’s New Weight Loss Drug Hit 22.7% — Here’s What That Means for Colorado Patients
CagriSema: Novo Nordisk’s New Weight Loss Drug Hit 22.7% — Here’s What That Means for Colorado Patients
Novo Nordisk’s stock dropped 9% the day the CagriSema results landed. Investors were hoping for 25%. They got 22.7%. Let that sink in: Wall Street treated a drug that produces the greatest weight loss in obesity medicine as a disappointment. Meanwhile, patients in my Greenwood Village clinic have been asking about it for months.
CagriSema isn’t a new GLP-1. It’s two medications in one weekly injection: semaglutide (the GLP-1 in Wegovy) plus cagrilintide, an amylin analog that works on a different hormonal pathway to suppress appetite. Two mechanisms. One shot.
What the Trials Show
The REDEFINE 1 trial enrolled adults with obesity or overweight — without type 2 diabetes — and dosed them weekly for 68 weeks. Result: 22.7% mean body weight reduction. That’s a 250-pound person losing roughly 57 pounds. For context, semaglutide alone typically produces around 15% in comparable trials. Nearly 92% of REDEFINE 1 participants lost at least 5% of their starting weight.
For patients with type 2 diabetes, REDEFINE 2 showed 15.7% average weight loss at 68 weeks. The REIMAGINE 2 trial — also in type 2 diabetes — showed a 1.91%-point HbA1c reduction alongside 14.2% weight loss. Both trials used a once-weekly injection.
The FDA submission came in December 2025, based on REDEFINE 1 and REDEFINE 2 data. The results landed in The New England Journal of Medicine and were presented at the ADA’s 85th Scientific Sessions.
Why Two Hormones Beat One
GLP-1 drugs like semaglutide mimic glucagon-like peptide-1 — a hormone that slows gastric emptying and signals fullness to the brain. Cagrilintide mimics amylin, a separate hormone secreted at the same time as insulin that independently promotes satiety after meals. They work through distinct pathways. Combining them produces results neither can achieve alone.
This matters for the patients I see across Denver and the Front Range who’ve been on a GLP-1 for six months or more and hit a wall. If you’ve been doing everything right and the scale stopped moving, the amylin pathway is where your physician might look next.
Bottom Line
CagriSema isn’t approved yet — FDA timing depends on the review process. But when it arrives, it will likely be the most effective obesity medication in our toolkit. For patients who’ve plateaued on current therapies, this is the development to ask your doctor about.
If you want a board-certified obesity physician in the Denver area tracking these developments closely, give us a call — (303) 750-9454.
Frequently Asked Questions
What is CagriSema and how does it work?
CagriSema is a combination of semaglutide (the GLP-1 hormone mimic in Wegovy) and cagrilintide (an amylin analog). Both hormones act on different appetite pathways — semaglutide through GLP-1 signaling and cagrilintide through amylin signaling — making the combination more effective than either alone.
How effective is CagriSema for weight loss?
In the REDEFINE 1 Phase III trial, participants with obesity lost an average of 22.7% of body weight at 68 weeks — roughly 57 pounds for a 250-pound person. Nearly 92% of participants lost at least 5% of their starting weight.
What about patients with type 2 diabetes?
In REDEFINE 2, participants with type 2 diabetes lost 15.7% average body weight. REIMAGINE 2 showed a 1.91%-point HbA1c reduction alongside 14.2% weight loss at 68 weeks.
Is CagriSema available now?
No. Novo Nordisk submitted CagriSema to the FDA in December 2025. FDA review timing depends on the agency. When approved, it will likely be the most effective obesity medication available.
Where can Colorado patients learn more about weight loss medications?
Clinical Nutrition Center in Greenwood Village offers physician-guided obesity care. Call (303) 750-9454 or visit clinicalnutritioncenter.com.
Ethan Lazarus, MD, MFOMA
Clinical Nutrition Center
5995 Greenwood Plaza Blvd, Suite 150
Greenwood Village, CO 80111
(303) 750-9454
